Form 8-K - Current report:
SEC Accession No. 0001437749-22-017612
Filing Date
2022-07-22
Accepted
2022-07-22 16:20:22
Documents
16
Period of Report
2022-07-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20220721_8k.htm   iXBRL 8-K 35019
2 EXHIBIT 1.1 ex_398222.htm EX-1.1 267726
3 EXHIBIT 5.1 ex_398223.htm EX-5.1 13251
8 ex_398223img001.jpg GRAPHIC 2586
  Complete submission text file 0001437749-22-017612.txt   522190

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA dffn-20220722.xsd EX-101.SCH 3601
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20220722_def.xml EX-101.DEF 11532
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20220722_lab.xml EX-101.LAB 15414
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20220722_pre.xml EX-101.PRE 11688
10 EXTRACTED XBRL INSTANCE DOCUMENT dffn20220721_8k_htm.xml XML 2578
Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

EIN.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 221100142
SIC: 2834 Pharmaceutical Preparations